Oral-Absorption-Enhancing Drug-Delivery Technology - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Oral-Absorption-Enhancing Drug-Delivery Technology
The authors examine an oral-absorption-enhancement technology based on surface-active materials to increase apical membrane fluidity in vitro.

Pharmaceutical Technology
Volume 35, pp. s12-s14

Safety studies. The enhancer excipients used in GIPET were developed due to their known safety as approved food additives. Several regulatory bodies have reviewed the data on safety and concluded that the materials in GIPET formulations have low toxicity potential (6). Phase I and II studies showed that exposures could be given safely on a repeated basis.

Table I: Timing of effect of GIPET I on human intestinal permeability using urinary execretion of polar sugars as a surrogate marker.
A legitimate concern with intestinal absorption-promoting technologies is the impact on general intestinal permeability. Although the clinical experience thus far has not suggested that this concern is an issue in vivo, intestinal-permeability studies were carried out in human subjects after intrajejunal administration of GIPET I, followed by tracer molecules with low oral absorption largely restricted to the paracellular route. The aim was to establish intestinal permeability recovery time in the presence of typical components of a GIPET formulation. The polar sugar, mannitol (molecular weight of 182.17 g/mol), is absorbed paracellularly across the gut and is excreted unchanged in the urine. Oral bioavailability of mannitol is approximately 25%, and this amount appears in the urine because it is freely filtered and not reabsorbed by renal tubules. Another polar disaccharide sugar, lactulose (molecular weight of 342.30 g/mol), also is absorbed paracellularly, but only to a level of 1% due to its larger molecular radius. The ratio of the urinary excretion is a well-established noninvasive indicator of human intestinal paracellular permeability in vivo (7). When the intestinal barrier function is compromised, the urinary lactulose-to-mannitol excretion ratio (LMER) increases because lactulose absorption is preferentially increased. In an open-label, partially randomized study using up to 24 human subjects, the marker molecules were given orally at 20, 40, or 60 min following intrajejunal instillation of GIPET I. The combined data showed that only when the sugars were administered 20 min after the fatty acid, the urinary LMER ratio increased (see Table I). Therefore, in subjects receiving three separate doses of GIPET I, the effect of the agent on intestinal permeability was very small (Aspirin has been reported to increase permeability as much as 40 times more than GIPET)(8). The observed increases were reversed quickly (i.e., no effect at 40 min). The three doses of GIPET I were considered safe and well tolerated in the human subjects.

Table II: Phase I oral bioavailability data with GIPET.
Phase I clinical studies. Although rodent and canine oral delivery data with absorption-promoting technologies can be impressive, significant differences in the intestinal physiology of species suggest that the only true species model for humans is human (9). Studies to date of GIPET in man have focused on different types of Biopharmaceutics Classification Scheme (BCS) Class III compounds, including small-molecule bisphosphonates (e.g., alendronate and zolendronate), a polysaccharide (e.g., low molecular-weight heparin, and peptides (e.g., desmopressin and acyline). All Phase I clinical studies showed a significant increase in oral bioavailability where absorption in control patients was negligible and showed that the GIPET platform can deliver therapeutic levels of these BCS Class III molecules (see Table II). The preclinical and clinical development results for one model molecule, acyline, are presented.

Figure 3: Acyline serum levels achieved: Figure 3(a) shows results from a preclinical dog model; Figure 3(b) shows results from Phase I clinical studies for GIPET-enhanced acyline.
Acyline, a decapeptide, is a gonadotropin-releasing hormone (GnRH) antagonist that suppresses luteinizing hormone and testosterone in man. It has the potential to treat hormone-dependent conditions, such as prostate and breast cancer, or to treat benign conditions, such as endometriosis. However, for therapeutic use, it currently has to be injected, which limits its clinical utility. Also, acyline is difficult to formulate as an injectable because it tends to form a gel. This gel results in a sustained-release injection, which is not always desirable to maximize therapeutic benefit. As a result, there is a clinical need for orally active GnRH antagonists, such as acyline. Proceeding from positive data in the preclinical dog model, the authors investigated GIPET-enhanced oral acyline in eight healthy men (18–55 years of age) in a PK and PD study (see Figure 3). Oral acyline was administered on three occasions, each separated by one week. The subjects received progressively increasing doses of 10, 20, and 40 mg of GIPET-acyline after an overnight fast and continued to fast for four hours post dose. Blood for the measurement of serum-leutinizing hormone, follicle-stimulating hormone (FSH), testosterone, and acyline was obtained before each dose of GIPET-acyline and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 48 h and 7 days after each dose. Complete blood counts and comprehensive metabolic panels were obtained 24 h after each dose for assessment of safety.

Figure 4: Testosterone levels following administration of 10-, 20-, and 40-mg GIPET-enhanced acyline tablets. GIPET is a registered trademark of Merrion Pharmaceuticals.
Results showed that mean serum acyline concentrations rose immediately after oral administration with all three doses and were undetectable in all subjects 48 h after dosing, except for one subject in the 40-mg group. Due to the large degree of variability between subjects, there were no significant differences in the PK parameters between doses. Acyline was not detected in the serum of any subject seven days after dosing (see Table III). Serum LH, FSH, and testosterone were significantly suppressed by all doses of GIPET-acyline after 6 h, with maximum suppression 12 h post dose. The average suppression of serum FSH 12 h post-dose was 28 5% compared to 70 10% suppression of serum LH. The difference is most likely due to the fourfold greater serum half-life of FSH compared to LH (320 versus80 min). The suppression of testosterone closely matched that of LH, with levels below the lower limit of the normal range(< 8.4 nmol/L) 12 h after the 40-mg dose (see Figure 4).

Table III: Oral acyline pharmacokinetic parameters.
A repeat dose study of GIPET-acyline showed a similar PK profile with no accumulation of drug. The acyline Phase I clinical studies clearly showed the clinical potential for this advanced drug-delivery platform.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here